Cue Biopharma, Inc.

CUENASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
22.91 USD
↘ 1.45 (5.95%)AT CLOSE (03:59 PM EDT)
23.32
↗ 0.41 (1.80%)
POST MARKET (AS OF 04:06 PM EDT)
Post Market
AS OF 04:06 PM EDT
23.32
↗ 0.41 (1.80%)
🟢Market: OPEN

CUE is currently priced at $23.32. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity and a bullish Golden Cross on the moving averages. On valuation, CUE trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Oct 5, 2026.

Open?$24.22
High?$24.87
Low?$22.87
Prev. Close?$24.36
Volume?168.4K
Avg. Volume?351.7K
VWAP?$23.85
Rel. Volume?0.48x
Bid / Ask
Bid?$22.95 × 100
Ask?$26.36 × 100
Spread?$3.41
Midpoint?$24.66
Valuation & Ratios
Market Cap?177.0M
Shares Out?7.3M
Float?3.5M
Float %?87.6%
P/E Ratio?N/A
P/B Ratio?76.61
EPS?-$22.59
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Immunology & Autoimmune
Employees
29
Market Cap
177.0M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.cuebiopharma.com
Listed
2018-01-02
Address
40 GUEST STREET
BOSTON, MA 02135
Phone: 617-949-2680
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
0
Momentum?
23
Short Sent.?
46
Piotroski F-Score?2/9Weak
Altman Z-Score?-29.44Distress
Confidence?59%Low
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?9.37%Elevated
Short Interest?332.1K
Days to Cover?2.4
Free Float3.5M
Avg Daily Volume136.3K
Settlement Date2026-09-15
Financial Health
Current Ratio?1.25Adequate
Quick Ratio?1.25Adequate
Cash Ratio?0.82Adequate
Debt/Equity?0.42Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
3
76.61HIGH▾
P/S?
Peers
100
S&P
31
4.70FAIR▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.7CHEAP▾
EV/Sales?
Peers
100
S&P
43
4.26FAIR▾
Returns & Efficiency
ROE?
S&P
3
-7,104.2%WEAK▾
ROA?
S&P
3
-534.4%WEAK▾
Cash Flow & Enterprise
FCF?$-50167000
Enterprise Value?$160.5M
Fundamentals ratios updated end of day
MarketsMoversWatchlist